1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Andros Pharmaceuticals Co., Ltd.

Andros Pharmaceuticals Co., Ltd.

TTPEX:6917
32.00
TWD
-0.45
(-1.39%)
1.70BMarket Cap
Andros Pharmaceuticals Co., Ltd.
TPEX:6917
(Taipei Exchange)

Recent

price

32.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
TWD
0.01
0.12
0.48
0.05
0.02
- -
0.12
- -
Revenue per Share
-2.12
-1.29
-1.33
-1.21
-1.82
-1.75
-1.16
- -
Basic EPS, GAAP
-1.98
-1.04
-1.28
-1.05
-1.26
-1.86
-1
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
3.34
2.38
1.81
7.35
10.21
8.54
9.33
8.79
Book Value per Share
3.34
2.38
1.81
7.35
10.21
8.54
9.33
8.79
Tangible Book Value per Share
27
28
28
34
38
45
46
51
Basic Weighted Avg Shares
- -
3
13
2
1
- -
6
- -
Sales/Revenue/Turnover
-41,159.18
-1,298.68
-262.19
-2,729.77
-9,156.52
-44,142.86
-1,363.3
- -
Operating Margin (%)
9
7
7
6
6
6
7
- -
Depreciation Expense
-58
-36
-37
-41
-68
-78
-54
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-39,418.37
-1,098.13
-278.92
-2,403.74
-8,466.96
-38,561.08
-969.29
- -
Profit Margin (%)
116
80
61
248
421
338
356
322
Working Capital
39
34
30
26
22
17
12
10
LT Debt
127
90
69
279
471
394
516
486
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-33.04
-46.7
-23.65
-18.16
-18.09
-11.82
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
5
5
5
LT Borrowings
- -
- -
- -
LT Finance Leases
14
12
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
47
55
55
Market Capitalization
760
1,343
1,702

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
279
383
349
Cash, Cash Equivalents & STI
267
370
334
Accounts Receivable, Net
- -
1
- -
Inventories
1
2
2
Total Current Liabilities
20
27
27
Payables & Accruals
- -
- -
- -
ST Debt
5
5
5
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
73.22%
30.84%
Free Cash Flow
- -
17.68%
-44.34%
Net Income, GAAP
- -
12.69%
-31.3%
Sales/Revenue/Turnover
- -
545.09%
2,633%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
6
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-1.75
2025
- -
- -
-1.16
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Andros Pharmaceuticals Co., Ltd. is a biopharmaceutical enterprise dedicated to advancing innovative drug delivery platform technologies. The firm is progressing APC101, a spray-formulated treatment for post-herpetic neuralgia, which has completed Phase II clinical trials and is now preparing for its Phase III application, with submission for Phase IIb/III clinical trial approval underway in Australia. Additionally, APC201, a foam-based topical anesthetic designed for osteoarthritis discomfort, concluded its Phase II studies, with a comprehensive data report anticipated in the first half of the current year, leading to plans for a global multi-center Phase III study and international licensing initiatives. The company's pipeline further encompasses novel solutions for DNA repair and gene therapy, including oligonucleotide and small interfering RNA (siRNA) candidates, alongside preclinical projects like APC310 and APC501 for various anesthetic applications, and APC401 for post-surgical pain relief. Beyond its developmental assets, Andros offers LALP cream for dermatological analgesic uses, which has achieved market approval and a licensing agreement in Hong Kong, and LTC Cream, a 7% Lidocaine/7% Tetracaine formulation, recognized in Taiwan as a pioneering topical dermatological generic drug under new regulatory standards. Established in 2008, Andros Pharmaceuticals Co., Ltd. operates from its headquarters in Zhubei, Taiwan.